More Data Will Inform Place of SGLT2 Inhibitors in DiabetesMore Data Will Inform Place of SGLT2 Inhibitors in Diabetes
A comparison of canagliflozin with glimepiride as an add-on to metformin in type 2 diabetes adds some knowledge to help guide use of the new SGLT2 inhibitors. But more will be needed, says an editorial. Medscape Medical News
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
More News: Diabetes | Diabetes Type 2 | Endocrinology | Fortamet | Glimepiride | Health | Metformin | SGLT2 Inhibitors